Sudarshan Pharma Industries Profile
Key Indicators
- Authorised Capital ₹ 35.00 Cr
- Paid Up Capital ₹ 24.07 Cr
- Company Age 16 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 105.81 Cr
- Satisfied Charges ₹ 4.25 Cr
- Revenue Growth 84.67%
- Profit Growth 96.53%
- Ebitda 52.16%
- Net Worth 32.31%
- Total Assets 38.80%
About Sudarshan Pharma Industries
Sudarshan Pharma Industries Limited (SPIL) is a leading Public Limited Indian Non-Government Company incorporated in India on 23 July 2008 and has a history of 16 years and six months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Sudarshan Speciality Chemsolve Private Limited. The Company is engaged in the Chemicals And Resources Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 35.00 Cr and a paid-up capital of Rs 24.07 Cr.
The company currently has active open charges totaling ₹105.81 Cr. The company has closed loans amounting to ₹4.25 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Sudarshan Pharma Industries Limited India is Ishita Samani as COMPANY SECRETARY. Rushabh Patil, Umesh Luthra, Sachin Mehta, and Two other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51496MH2008PLC184997
- Company No.
184997
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
23 Jul 2008
- Date of AGM
02 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc-Mumbai
Industry
What products or services does Sudarshan Pharma Industries Limited offer?
Sudarshan Pharma Industries Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Zinc salts, Paints, Wall Putty & Varnishes, Paint Thinners, Fertilizers and Soil Additives, Sulfur Fertilizers, Industrial Chemicals & Supplies, Rocket Propellants, Organic and Inorganic Solvents, Alcohol Solvents.
Who are the key members and board of directors at Sudarshan Pharma Industries?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hemal Mehta  | Managing Director | 23-Jul-2008 | Current |
| Ishita Samani | Company Secretary | 17-Dec-2022 | Current |
| Sachin Mehta | Managing Director | 23-Jul-2008 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jaya Singhania | Director | 27-Dec-2022 | Current |
| Rushabh Patil | Director | 21-Jul-2023 | Current |
| Umesh Luthra | Director | 31-Jan-2022 | Current |
Financial Performance of Sudarshan Pharma Industries.
Sudarshan Pharma Industries Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 84.67% increase. The company also saw a substantial improvement in profitability, with a 96.53% increase in profit. The company's net worth Soared by an impressive increase of 32.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sudarshan Pharma Industries?
In 2021, Sudarshan Pharma Industries had a promoter holding of 92.78% and a public holding of 7.22%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vi Furnishings Private LimitedJaya Singhania is a mutual person
Krishna Solvechem LimitedJaya Singhania is a mutual person
Sudarshan Solvents Industries LimitedSachin Mehta and Hemal Mehta are mutual person
Eguardian Global Services India Private LimitedJaya Singhania is a mutual person
Brandzstorm India Marketing Private LimitedIshita Samani is a mutual person
Jet Freight Logistics LimitedRushabh Patil and Jaya Singhania are mutual person
Charges (Loans)
₹105.81 Cr
₹4.25 Cr
Charges Breakdown by Lending Institutions
- Kotak Mahindra Bank Limited : 29.98 Cr
- Union Bank Of India : 27.46 Cr
- Axis Bank Limited : 25.50 Cr
- Icici Bank Limited : 20.60 Cr
- Tata Capital Financial Services Limited : 1.90 Cr
- Others : 0.38 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Sep 2023 | Kotak Mahindra Bank Limited | ₹29.98 Cr | Open |
| 15 Nov 2022 | Icici Bank Limited | ₹12.00 Cr | Open |
| 27 Oct 2022 | Icici Bank Limited | ₹8.60 Cr | Open |
| 30 Sep 2022 | Tata Capital Financial Services Limited | ₹3.99 M | Open |
| 30 Sep 2022 | Hdfc Bank Limited | ₹3.75 M | Open |
How Many Employees Work at Sudarshan Pharma Industries?
Sudarshan Pharma Industries has a workforce of 7 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sudarshan Pharma Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sudarshan Pharma Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
